Neuroendocrine Tumors Clinical Trials

26 studies are recruiting for neuroendocrine tumors in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Bethesda, Maryland 7 Philadelphia, Pennsylvania 7 Salt Lake City, Utah 5 Atlanta, Georgia 4 Duarte, California 4 Houston, Texas 4 Iowa City, Iowa 4 Miami, Florida 4 Nashville, Tennessee 4 Portland, Oregon 4 San Francisco, California 4 Charlottesville, Virginia 3 Cleveland, Ohio 3 Columbus, Ohio 3 Detroit, Michigan 3 Jacksonville, Florida 3 Lexington, Kentucky 3 New York, New York 3 Omaha, Nebraska 3 Phoenix, Arizona 3 Rochester, Minnesota 3 St Louis, Missouri 3

Studies now recruiting

  1. EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

    This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin). This study has 3 c…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
    Run by
    Case Comprehensive Cancer Center

    See if you can join NCT06263088 on ClinicalTrials.gov

  2. Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

    The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Facility, Phoenix, Arizona
    Locations
    14 in total
    Run by
    RayzeBio, Inc.

    See if you can join NCT07165132 on ClinicalTrials.gov

  3. Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

    Background: A neuroendocrine tumor is a rare type of tumor. It comes from body cells called neuroendocrine cells. Sometimes, these tumors develop in the gastrointestinal tract and pancreas. Researchers want to find out if a combination of drugs can shrink these tumors. Objective: To learn if people…

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT04086485 on ClinicalTrials.gov

  4. Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

    Background: Pheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region. Not all these tumors can be removed with surgery, and there are no good treatments if the disease has spread. Researchers think a new drug may be able to help. …

    Stage
    Phase 2
    Ages
    18 to 100
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT03206060 on ClinicalTrials.gov

  5. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

    Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs…

    Stage
    Phase 2
    Ages
    18 to 72
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT03412877 on ClinicalTrials.gov

  6. The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)

    The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT07151391 on ClinicalTrials.gov

  7. A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

    This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Crinetics Study Site, Phoenix, Arizona
    Locations
    27 in total
    Run by
    Crinetics Pharmaceuticals Inc.

    See if you can join NCT07129252 on ClinicalTrials.gov

  8. Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

    This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Run by
    Fox Chase Cancer Center

    See if you can join NCT05263050 on ClinicalTrials.gov

  9. Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

    Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite its demonstrated potential, immunotherapy is no…

    Stage
    Phase 1
    Ages
    18 to 99
    Site
    University of Florida, Gainesville, Florida
    Run by
    University of Florida

    See if you can join NCT05000294 on ClinicalTrials.gov

  10. Integrated Cancer Repository for Cancer Research

    The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

    Stage
    Not phased
    Ages
    19 to 110
    Site
    Advent Health, Greenwood Village, Colorado
    Locations
    42 in total
    Run by
    University of Nebraska

    See if you can join NCT02012699 on ClinicalTrials.gov

  11. A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

    Background: Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of relapse and a low chance of survival. Better treatments are needed. Objective: To test a new drug, ADCT…

    Stage
    Phase 1
    Ages
    18 to 120
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06041516 on ClinicalTrials.gov

  12. CapTemY90 for Grade 2/3 NET Liver Metastases

    This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation f…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UC San Diego, La Jolla, California
    Locations
    4 in total
    Run by
    Abramson Cancer Center at Penn Medicine

    See if you can join NCT04339036 on ClinicalTrials.gov

  13. SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

    The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3. The highest dose…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Miami, Miami, Florida
    Run by
    Peter Hosein, MD

    See if you can join NCT06889493 on ClinicalTrials.gov

  14. Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

    This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapa…

    Stage
    Phase 1
    Ages
    20 to 99
    Site
    Stanford University, Palo Alto, California
    Locations
    2 in total
    Run by
    Teclison Ltd.

    See if you can join NCT02174549 on ClinicalTrials.gov

  15. Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

    Background: People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect th…

    Stage
    Phase 2
    Ages
    12 and older
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT04074135 on ClinicalTrials.gov

  16. Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated,…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Facility, Irvine, California
    Locations
    54 in total
    Run by
    RayzeBio, Inc.

    See if you can join NCT05477576 on ClinicalTrials.gov

  17. Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

    The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Clinical Research Institute at Methodist Health System, Dallas, Texas
    Locations
    2 in total
    Run by
    Methodist Health System

    See if you can join NCT04090034 on ClinicalTrials.gov

  18. Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

    This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study ag…

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    City of Hope, Duarte, California
    Locations
    3 in total
    Run by
    Anusha Kalbasi

    See if you can join NCT04119024 on ClinicalTrials.gov

  19. Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

    This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). First described in the pancreas in 2017, the classification was broadened to include gastrointestinal tract tumors in 2019. Recent data sugg…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of California, San Francisco, San Francisco, California
    Run by
    University of California, San Francisco

    See if you can join NCT05746208 on ClinicalTrials.gov

  20. A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

    The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

    Stage
    Phase 1
    Ages
    18 to 85
    Site
    Emory University, Atlanta, Georgia
    Locations
    4 in total
    Run by
    Chimeric Therapeutics

    See if you can join NCT06055439 on ClinicalTrials.gov

  21. F-Tryptophan PET/CT in Human Cancers

    Imaging procedures such as 1-(2-[18F]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Karmanos Cancer Institute, Detroit, Michigan
    Run by
    Barbara Ann Karmanos Cancer Institute

    See if you can join NCT05556473 on ClinicalTrials.gov

  22. Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

    Background: Neuroendocrine neoplasm (NENs)are rare cancers arising from the neuroendocrine cells and can affect almost any part of the body. They vary from low grade neuroendocrine tumors (NETs) to high grade neuroendocrine carcinomas (NECs). These tumors often occur in the gastrointestinal tract, …

    Stage
    Not phased
    Ages
    18 to 120
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT05237934 on ClinicalTrials.gov

  23. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Birmingham, Alabama
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  24. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Michigan Hospitals, Ann Arbor, Michigan
    Locations
    5 in total
    Run by
    Novelty Nobility, Inc.

    See if you can join NCT06805825 on ClinicalTrials.gov

  25. Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

    The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan. Main questions to answer are: * Can we have a completion rate of at least 80% of participan…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Karmanos Cancer Institute, Detroit, Michigan
    Run by
    Barbara Ann Karmanos Cancer Institute

    See if you can join NCT06908629 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.